Table 3 The concentrations of tested biomarkers in patients with COVID-19 treated with dexamethasone and without such treatment.

From: Clinical usefulness of the serum levels of neuroinflammatory and lung fibrosis biomarkers in the assessment of cognitive dysfunction in post-COVID19 patients

Variables

Group A without dexamethasone (n = 22)

p value gr.A v.1 vs. v.2

Group B with dexamethasone (n = 14)

p value gr.B v.1 vs. v.2

Visit 1

Visit 2

Visit 1

Visit 2

YKL-40, ng/ml (median, range)

36.63 (8.31-185.86)

37.11 (8.98-279.29)

0.566

59.56 (17.25-177.45)

33.66 (15.52-233.43)

0.05

YKL-40 1:2 ratio, (median, range)

0.77 (0.13–2.30)

  

1.41 (0.32–5.50)

  

MR-pro-ADM, pmol/l (median, range)

635.48 (127.11-1757.72)

475.15 (338.22-1485.09)

0.130

620.52 (174.27-2173.03)

536.33 (194.91-2393.74)

0.509

MR-pro-ADM 1:2 ratio, (median, range)

1.16 (0.38–1.75)

  

1.10 (0.38–3.96)

  
  1. Abbreviations: MR-pro-ADM - Mid regional pro-adrenomedullin, YKL-40 - Chitinase-3-like protein 1.
Back to article page